TD Waterhouse Canada Inc. Sells 70,572 Shares of Gilead Sciences, Inc. $GILD

Key Points

• TD Waterhouse Canada reduced its Gilead Sciences position by 12.8%, selling 70,572 shares and retaining 482,201 shares valued at approximately $60.8 million. Institutional investors collectively own 83.67% of Gilead.
• Analysts maintain a “Moderate Buy” consensus on Gilead, with an average price target of $158.04, although several firms recently lowered targets while one upgraded the stock to “Buy.”
• Gilead reported quarterly revenue of $7.80 billion, up 10.6% year over year and above estimates, while narrowing its expected loss per share. The company also declared a quarterly dividend of $0.82 per share, equivalent to a 2.2% annualized yield.

TD Waterhouse Canada Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 482,201 shares of the biopharmaceutical company's stock after selling 70,572 shares during the period. TD Waterhouse Canada Inc.'s holdings in Gilead Sciences were worth $60,789,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in GILD. BlackRock Inc. bought a new stake in Gilead Sciences in the 2nd quarter worth approximately $15,393,785,000. Norges Bank bought a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $2,617,152,000. Legal & General Group Plc purchased a new position in shares of Gilead Sciences in the second quarter valued at $1,316,606,000. Deutsche Bank AG purchased a new position in shares of Gilead Sciences in the second quarter valued at $918,387,000. Finally, Boston Partners bought a new stake in Gilead Sciences in the fourth quarter worth $517,808,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GILD. Barclays decreased their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 29th. Leerink Partners downgraded shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Maxim Group upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 target price on the stock in a report on Wednesday, May 20th. Rothschild & Co Redburn decreased their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Finally, Truist Financial dropped their price target on Gilead Sciences from $157.00 to $156.00 and set a "buy" rating for the company in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $158.04.

Gilead Sciences Stock Up 1.1%

Shares of GILD opened at $151.22 on Friday. The company has a market cap of $187.51 billion, a PE ratio of -56.64 and a beta of 0.33. The business has a fifty day moving average of $136.21 and a 200 day moving average of $136.42. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same period in the previous year, the firm earned $2.01 earnings per share. Gilead Sciences's quarterly revenue was up 10.6% compared to the same quarter last year. On average, sell-side analysts expect that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences's payout ratio is currently -122.85%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the sale, the chief financial officer directly owned 165,646 shares of the company's stock, valued at $22,918,780.56. This represents a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the sale, the insider owned 118,234 shares in the company, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock worth $14,495,820 in the last three months. 0.30% of the stock is owned by insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts raised Gilead’s earnings forecasts and upgraded the stock to “Strong Buy.” Zacks increased its 2027 quarterly EPS estimates and lifted its full-year forecast to $9.36 from $9.30. It also raised its FY2028 estimate to $9.66 from $9.58, suggesting expectations for improving profitability. Zacks upgrade and earnings estimates
• Positive Sentiment: Gilead’s latest results provided a favorable foundation for the rally. The company reported quarterly revenue of $7.80 billion, above the $7.40 billion consensus estimate, while its loss per share was narrower than expected. Revenue increased 10.6% year over year, giving investors confidence in the business despite currently negative reported earnings. Gilead post-earnings performance
• Positive Sentiment: A partner-backed stomach-cancer trial reached completion, creating a potential immuno-oncology catalyst. The milestone involving Arcus-supported research could provide important future data for Gilead’s oncology strategy, although the eventual investment impact depends on trial results and regulatory progress. Gilead cancer trial milestone
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The sale reduced his ownership by 2.53%, but it was conducted under a pre-arranged Rule 10b5-1 trading plan, making it a limited bearish signal. SEC insider trading filing

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source